

On 2017/02/28 21:03, Joyce, Tom wrote:

Dear Mr. Vandavelde and Leaders of the TB Community Advisory Board:

Thank you for your January 17, 2017 letter highlighting the significant contribution of the GeneXpert® and Xpert® MTB/RIF in the fight against tuberculosis around the world, as well as the need to continue with the development of new products in this important field. We appreciate Cepheid's achievements in the Global Health arena.

Cepheid became a fully owned Operating Company (OpCo) of Danaher early in November 2016. As such, and along with our operating principles, Cepheid operations will continue under the leadership of the Cepheid management team. Within Danaher, decision-making is decentralized and will benefit from leveraging the strength of a broader set of diagnostic entities, enhancing our product and service offerings. The implementation within Cepheid of our Danaher Business System will ensure best practice in operations, commercial and technical processes toward continuous improvement of our activities.

The definition of strategies and programs are under the responsibility of the OpCo and I would, therefore, recommend that you continue to interact directly with the Cepheid team, in particular with its President, Warren Kocmond and with Philippe Jacon, President of the High Burden and Developing Country (HBDC) program with whom you are most certainly already familiar, as they will continue to be the right leaders to plan and agree on continued programs, with the authority to do so.

I have asked Warren and Philippe, copied here, to respond to your letter in more detail as soon as practical.

Thank you,

Tom Joyce